Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951690 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Verastem.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT01951690 is a Phase 2 study that has completed, run by Verastem. The registered enrollment target is 55 participants.
The verdict
NCT01951690, a Phase 2 study, has completed, sponsored by Verastem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a Phase II, open-label, multicenter, multi cohort, study of VS-6063 (defactinib), a focal adhesion kinase inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). NSCLC with a KRAS mutation is required for study entry and subjects will be enrolled into 1 of 4 cohorts based on the status of their INK4a/Arf and p53 mutations. The purpose of this study is to demonstrate if VS-6063 (defactinib) improves PFS within each cohort. The safety and tolerability of VS-6063, tumor response rate, progression free survival and overall survival will also be assessed. The pharmacodynamic effects of VS-6063 (defactinib) will be examined in a tumor biopsy and a blood sample.
Interventions
- DRUG defactinib (VS-6063)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01951690
The ClinicalTrials.gov registry entry for NCT01951690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which defactinib (VS-6063) is the first listed.
NCT01951690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01951690 about?
NCT01951690 is a clinical study titled "Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer". This is a Phase II, open-label, multicenter, multi cohort, study of VS-6063 (defactinib), a focal adhesion kinase inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). NSCLC with a KRAS mutation is required for study entry and subjects will be enrolled into 1 of 4 cohorts based...
What is the current status of trial NCT01951690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2013-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01951690?
The interventions under investigation include: defactinib (VS-6063) (DRUG).
Who is sponsoring clinical trial NCT01951690?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.